Payment overview · 2025
General Payments
$185.43
8 reported records · 5 companies
Healthcare provider profile · identity verified
Brooks Smith Lide, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · ATLANTA, GA · NPI 1083777056
Verified facts
What the public records show
CMS Open Payments records show Brooks Smith Lide, M.D. received $185.43 in general payments during 2025 across 8 reported records.
Radius Health, Inc. accounted for 35.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 120 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $66.13 | 35.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $50.34 | 27.1% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $31.55 | 17.0% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.08 | 10.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.33 | 9.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $185.43 | 8 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $66.13 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $50.34 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.08 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.33 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $15.33 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 120 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
120 | 24 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 493 | 141 |
| Amlodipine Besylate | Amlodipine Besylate | 338 | 88 |
| Levothyroxine Sodium | Levothyroxine Sodium | 294 | 68 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 225 | 66 |
| Losartan Potassium | Losartan Potassium | 192 | 52 |
| Zolpidem Tartrate | Zolpidem Tartrate | 184 | 41 |
| Ezetimibe | Ezetimibe | 179 | 48 |
| Lisinopril | Lisinopril | 140 | 40 |
| Trazodone Hcl | Trazodone Hcl | 138 | 45 |
| Omeprazole | Omeprazole | 128 | 43 |
| Eliquis | Apixaban | 120 | 24 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 39 |
| Gabapentin | Gabapentin | 106 | 25 |
| Pravastatin Sodium | Pravastatin Sodium | 102 | 26 |
| Hydrochlorothiazide | Hydrochlorothiazide | 101 | 27 |
| Meloxicam | Meloxicam | 97 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 95 | 24 |
| Simvastatin | Simvastatin | 89 | 21 |
| Escitalopram Oxalate | Escitalopram Oxalate | 86 | 28 |
| Alprazolam | Alprazolam | 81 | 17 |
| Sertraline Hcl | Sertraline Hcl | 81 | 27 |
| Amoxicillin | Amoxicillin | 80 | 59 |
| Metoprolol Succinate | Metoprolol Succinate | 75 | 23 |
| Metformin Hcl | Metformin Hcl | 67 | 20 |
| Pantoprazole Sodium | Pantoprazole Sodium | 66 | 22 |
| Lorazepam | Lorazepam | 64 | 16 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 60 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 57 | 24 |
| Allopurinol | Allopurinol | 50 | 13 |
| Duloxetine Hcl | Duloxetine Hcl | 50 | 14 |
| Carvedilol | Carvedilol | 49 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 13 |
| Metoprolol Tartrate | Metoprolol Tartrate | 49 | 16 |
| Tramadol Hcl | Tramadol Hcl | 44 | 15 |
| Valsartan | Valsartan | 44 | 12 |
| Bupropion Xl | Bupropion Hcl | 43 | suppressed |
| Celecoxib | Celecoxib | 43 | 14 |
| Finasteride | Finasteride | 43 | 16 |
| Metformin Hcl Er | Metformin Hcl | 43 | 15 |
| Synthroid | Levothyroxine Sodium | 40 | 11 |
| Xarelto | Rivaroxaban | 40 | 11 |
| Clopidogrel | Clopidogrel Bisulfate | 39 | 13 |
| Doxycycline Hyclate | Doxycycline Hyclate | 38 | 31 |
| Clonazepam | Clonazepam | 36 | 11 |
| Famotidine | Famotidine | 36 | 13 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 36 | 11 |
| Primidone | Primidone | 36 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 35 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 35 | 18 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 27 |
| Potassium Chloride | Potassium Chloride | 34 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 33 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Diazepam | Diazepam | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 29 | 28 |
| Methylprednisolone | Methylprednisolone | 27 | 26 |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 27 | 20 |
| Furosemide | Furosemide | 26 | suppressed |
| Colchicine | Colchicine | 23 | suppressed |
| Prednisone | Prednisone | 22 | 18 |
| Azithromycin | Azithromycin | 21 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 21 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 21 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 20 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 20 | suppressed |
| Estradiol | Estradiol | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Methylphenidate Hcl Cd | Methylphenidate Hcl | 20 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 20 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 19 | 17 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 19 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 19 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 18 | suppressed |
| Estradiol (Twice Weekly) | Estradiol | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Naproxen | Naproxen | 17 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 17 | suppressed |
| Atenolol | Atenolol | 16 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 16 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 16 | suppressed |
| Irbesartan | Irbesartan | 16 | suppressed |
| Ketoconazole | Ketoconazole | 16 | suppressed |
| Januvia | Sitagliptin Phosphate | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 15 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 14 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 13 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 13 | suppressed |
| Myrbetriq | Mirabegron | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Cefadroxil | Cefadroxil | 12 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 12 | suppressed |
| Desmopressin Acetate | Desmopressin (Nonrefrigerated) | 11 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 11 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 11 | suppressed |
| Glipizide Er | Glipizide | 11 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 11 | suppressed |
| Methylphenidate Hcl Er (Cd) | Methylphenidate Hcl | 11 | suppressed |
| Novolin N | Insulin Nph Human Isophane | 11 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 11 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 11 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 11 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $185.43 · 8 records | Radius Health, Inc. | ELIQUIS, GEMTESA, JARDIANCE, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, Tymlos | 2 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with PFIZER INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error